title: Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade?
authors.affiliation: Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Yasuda
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fujii
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yuasa
authors.forename: Shinya
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Junji
authors.initials: J
authors.lastname: Yonese
authors.forename: Iwao
authors.initials: I
authors.lastname: Fukui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D012189:Retrospective Studies; D016019:Survival Analysis; D013739:Testosterone / Q000097:blood*
chemical_list: D000726:Androgen Antagonists; D013739:Testosterone